Pernix Therapeutics (PTX) Announces Interim Results From Phase IV Study of Silenor and Zolpidem
Tweet Send to a Friend
Pernix Therapeutics (NASDAQ: PTX) today announced positive interim results from a Phase IV Study assessing the effects of a ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE